ENT Disorder Treatment Market, by Treatment Type (Devices (Hearing Aid Devices, Voice Prosthesis, Nasal Splints, Hearing Implants and Others) and Drug Type (Antibiotics, Antihistamines, Steroids, Anti-inflammatory Drugs, Others)), by Organ Type (Ear, Nose

ENT Disorder Treatment Market, by Treatment Type (Devices (Hearing Aid Devices, Voice Prosthesis, Nasal Splints, Hearing Implants and Others) and Drug Type (Antibiotics, Antihistamines, Steroids, Anti-inflammatory Drugs, Others)), by Organ Type (Ear, Nose, and Throat), by End User (Hospitals, Clinics, Ambulatory Surgical Centers, Home Care Settings, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

ENT also known as otolaryngology is a stream of medical science that deals with disorders associated with ear, nose, and throat. Diseases related to ears, throat, and nose significantly affect the quality of life and could lead to surgeries in few cases such as chronic tonsillitis, ear infections, and severe sinusitis problems as well as cancers of the throat or larynx, and others. In order to treat these disorders, ENT treatment is required. These diseases can either be treated with the help of devices or drugs, however, surgeries are recommended to patients with severe cases. Surgical procedures are required in few cases such as throat cancer as recommended by otolaryngologist, however, an oncologist performs the tumor removal procedures, which is either followed by a radiation or chemotherapy, depending on the severity.

Market Dynamics

Key players are focusing on inorganic growth strategies such as agreement and acquisitions for enhancement of research department as well as commercialization of products in terms of sales and marketing. For instance, in July 2017, Entellus Medical announced a definitive agreement to acquire Spirox, Inc. a privately held ENT medical technology that develops, manufactures and markets absorbable nasal implants and other medical devices.

Moreover, in August 2021, Medtronic plc., the global leader in medical technology signed agreement with Intersect ENT, a global ear, nose, and throat (ENT) medical technology leader dedicated to transforming patient care, in which Medtronic acquired all shares of Intersect ENT for US$28.25 per share in an all-cash transaction implying an enterprise value of approximately US$1.1 billion. The boards of directors of both companies have unanimously approved the transaction. Medtronic's acquisition of Intersect ENT expands the company's portfolio of products used during ear, nose, and throat procedures. The complementary product lines and Medtronic's efforts to have a positive impact for patients who suffer from chronic rhinosinusitis (CRS). Intersect ENT's PROPEL® and SINUVA® sinus implants are clinically proven solutions that open sinus passageways and deliver an anti-inflammatory steroid to aid in healing. By combining these products with Medtronic's navigation, powered instruments, and existing tissue health products, the company intends to offer a broader suite of solutions to assist surgeons treating CRS patients.

Key features of the study:

• This report provides an in-depth analysis of the global ENT disorder treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global ENT disorder treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Sanofi, AstraZeneca, Novartis AG, Pfizer Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Pharmaceuticals, Otonomy Inc., Merck & Co., Dr. Reddys Laboratories Ltd., Allergan plc, Cochlear Ltd., Sonova Holding AG, Siemens Healthcare, Starkey Laboratories Inc., William Demant Holding A/S, Widex A/S, GN ReSound A/S, Sonic Innovations Inc., Panasonic Corp., Beltone, Rexton Inc., Avada Hearing Care, Miracle-Ear Inc., MED-EL GmbH, Nuear Hearing Aids Inc., Audiosync Inc., Bernafon, American Hearing Systems Inc., Unitron Hearing Inc., and Zounds Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global ENT disorder treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ENT disorder treatment market

Detailed Segmentation:

• Global ENT Disorder Treatment Market, By Treatment Type:
• By Devices
• Hearing Aid Devices
• Voice Prostheses
• Nasal Splints
• Hearing Implants
• Others
• By Drugs
• Antibiotics
• Antihistamines
• Steroids
• Anti-inflammatory Drugs
• Others
• Global ENT Disorder Treatment Market, By Organ Type:
• Ears
• Nose
• Throat
• Global ENT Disorder Treatment Market, By End User:
• Hospital
• Clinics
• Ambulatory Surgical Centers
• Home Care Settings
• Others
• Global ENT Disorder Treatment Market, By Region:
• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Region/Country
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Sanofi *
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• AstraZeneca Plc
• Novartis AG
• Pfizer, Inc.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• GlaxoSmithKline Plc
• Otonomy, Inc.
• Merck & Co., Inc.
• Reddy’s Laboratories Ltd.
• Allergen Plc
• Cochlear, Ltd.
• Sonova Holdings AG
• Siemens Healthineers
• Starkey Laboratories, Inc.
• William Demant Holdings A/S
• Widex A/S
• GN ReSound A/S
• Sonic Innovations, Inc.
• Panasonic Corporation
• Beltone
• Rexton, Inc.
• Avada Hearing Care
• Miracle-Ear, Inc.
• MED-EL GmbH
• Nuear Hearing Aids Inc.
• AudioSync, Inc.
• Bernafon
• American Hearing Systems, Inc.
• Unitron Hearing, Inc.
• Zounds, Inc.

“*” marked represents similar segmentation in other categories in the respective section.